Skip to main content

Table 2 The distribution of virological failure per clinical factors at Tefera Hailu Memorial Hospital, Sekota, northeast Ethiopia, 2019

From: Antiretroviral treatment failure and associated factors among HIV patients on first-line antiretroviral treatment in Sekota, northeast Ethiopia

Variables

Category

N = 295

% from N

VTF = 49

%

Current ART regimen

1c

53

18.0

16

32.65

1d

82

27.8

12

24.49

1e

135

45.8

15

30.61

1f

16

5.4

2

4.08

4c

9

3.1

4

8.16

Baseline ART regimen

1a

26

8.8

4

8.16

1b

40

13.6

8

16.33

1c

37

12.5

8

16.33

1d

68

23.1

12

24.49

1e

110

37.3

11

22.45

4c

14

4.7

6

12.24

Drug substitution

None

208

70.5

31

63.27

Once

87

29.5

18

36.73

Current CD4 result

≤ 100

23

7.8

14

28.57

101–250

86

29.2

20

40.82

251–500

88

29.8

11

22.45

501 +

98

33.2

4

8.16

Current clinical stage

I

265

89.8

34

69.39

II

24

8.13

12

24.49

III

6

2.03

3

6.12

Baseline clinical stage

I

59

20.0

7

14.29

II

124

42.0

21

42.86

III

98

33.2

18

36.73

IV

14

4.7

3

6.12

The dose of ART per day

Once

131

44.4

15

30.61

Twice

164

55.6

34

69.39

Drug interruption

No

261

88.5

37

75.51

Yes

34

11.5

12

24.49

Drug adherence

≥ 95%

189

64.1

11

22.45

< 95%

106

35.9

38

77.55

Prophylaxis use

No

285

96.6

44

89.80

Yes

10

3.4

5

10.80

Baseline function status

Bedridden

28

9.5

7

14.29

Ambulatory

184

62.4

28

57.14

Working

83

28.1

14

28.57

TB history

No

242

82

36

73.47

Yes

53

18

13

26.53

Disclosure

No

71

24.1

10

20.41

Yes

224

75.9

39

79.59

Duration/month on ART

6–24

29

9.8

1

2.04

25–48

39

13.2

4

8.16

49–72

57

19.3

7

14.29

73 +

170

57.6

37

75.51

Baseline CD4 result

≤ 100

150

50.8

26

53.06

101–250

88

29.8

15

30.61

251–500

28

9.5

3

6.12

501 +

29

9.8

5

10.20

  1. 1a = d4T/3TC/NVP, 1b = d4T/3TC/NVP, 1c = AZT/3TC/NVP, 1d = AZT/3TC/EFV, 1f = TDF/3TC/NVP, 4c = AZT/3TC/NVP, VTF virological treatment failure, N total participants, TB tuberculosis